Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists
You may begin seeing changes in appetite suppression and possibly energy expenditure within the first few weeks of starting retatrutide, but significant body weight reduction tends to occur over months (24-48 weeks in trials show major changes)
Iron deficiency anaemia, in particular, is associated with feeling cold (NHS)
The Critical Birth Control Conversation This cannot be overstated: Use effective contraception while taking GLP-1 medications
While less potent than injectable options, the convenience of oral administration could make it a preferred first-line option
The therapeutic potential of GLP-1 receptor biased agonism
